banner
Integrin inhibitor, Fradafiban, Purity ≥98%
Inquiry

Cat. No.: X24-08-YM306

Integrin inhibitor, Fradafiban, Purity ≥98%

Synonym: 148396-36-5; BIBU-52; BIBU52; BIBU 52; 2-[(3S,5S)-5-[[4-(4-Carbamimidoylphenyl)phenoxy]methyl]-2-oxopyrrolidin-3-yl]acetic acid

  • CAS Number: 148396-36-5
  • Compound CID: 66000
img
Product Size
1 mg; 5 mg; 10 mg; 50 mg
Price
Datasheet
MSDS
Properties
Description
Fradafiban is an effective cytoskeleton inhibitor, that has the ability to prevent the pathway of cytoskeletal signaling by inhibiting integrin.
Molecular Weight
367.4
Molecular Formula
C20H21N3O4
Form
Lyophilized powder
Purity
≥98%
Titer
Free from inappropriate visible particulates, foreign matter, discoloration, or other defects
Applications
Fradafiban is a cytoskeletal signaling inhibitor that displays the significant potential to act as an effective anti-platelet agent to prevent thrombosis and cardiovascular events by inhibiting platelet aggregation.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products

About Us

CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.

Contact Us

  • For research and manufacturing partners only. Not intended for (direct) human or veterinary use.
Copyright © CD BioGlyco. All rights reserved.